clomipramine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
substances of the imipramine group	701	303-49-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: clomipramine chlorimipramine clomipramine hydrochloride clomipramine HCl	A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine. Molecular weight: 314.86 Formula: C19H23ClN2 CLOGP: 5.92 LIPINSKI: 1 HAC: 2 HDO: 0 TPSA: 6.48 ALOGS: -4.34 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

clomipramine
chlorimipramine
clomipramine hydrochloride
clomipramine HCl

A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.

Molecular weight: 314.86
Formula: C19H23ClN2
CLOGP: 5.92
LIPINSKI: 1
HAC: 2
HDO: 0
TPSA: 6.48
ALOGS: -4.34
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O
0.10	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	13.24 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	51 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	13 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	8.20 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.03 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	26 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 29, 1989	FDA	MALLINCKRODT LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	202.70	16.97	133	10277	56746	50537968
Intentional overdose	179.65	16.97	128	10282	62376	50532338
Serotonin syndrome	174.07	16.97	90	10320	24623	50570091
Drug interaction	146.30	16.97	192	10218	199429	50395285
Overdose	118.32	16.97	123	10287	99604	50495110
Bezoar	115.54	16.97	31	10379	1317	50593397
Suicide attempt	108.83	16.97	88	10322	51644	50543070
Poisoning deliberate	99.50	16.97	43	10367	7869	50586845
Intentional self-injury	94.49	16.97	59	10351	23053	50571661
Depressed level of consciousness	87.94	16.97	78	10332	51875	50542839
Toxicity to various agents	86.79	16.97	156	10254	212343	50382371
Antipsychotic drug level increased	82.29	16.97	29	10381	3080	50591634
Neuroleptic malignant syndrome	71.10	16.97	38	10372	11092	50583622
Sopor	67.09	16.97	45	10365	19834	50574880
Tachycardia	63.80	16.97	90	10320	99673	50495041
Antidepressant drug level increased	58.43	16.97	13	10397	248	50594466
Electrocardiogram QT prolonged	57.88	16.97	62	10348	51824	50542890
Pain	52.43	16.97	27	10383	578876	50015838
Hypertonia	51.28	16.97	22	10388	3951	50590763
Cerebellar syndrome	48.29	16.97	20	10390	3291	50591423
Myoclonus	47.02	16.97	32	10378	14438	50580276
Tremor	46.33	16.97	84	10326	114819	50479895
Sinus tachycardia	44.17	16.97	36	10374	21318	50573396
Agitation	43.08	16.97	54	10356	53330	50541384
Somnolence	43.02	16.97	97	10313	154888	50439826
Confusional state	42.59	16.97	108	10302	185820	50408894
Livedo reticularis	41.71	16.97	16	10394	2156	50592558
Suicidal ideation	41.50	16.97	54	10356	55331	50539383
Akathisia	41.36	16.97	24	10386	8205	50586509
Altered state of consciousness	41.29	16.97	35	10375	21875	50572839
International normalised ratio abnormal	40.88	16.97	17	10393	2826	50591888
Psychomotor hyperactivity	38.64	16.97	24	10386	9277	50585437
Ventricular dyskinesia	37.52	16.97	8	10402	124	50594590
Hyposmia	36.83	16.97	10	10400	444	50594270
Hyperchloraemia	36.83	16.97	11	10399	690	50594024
Drug abuse	36.76	16.97	53	10357	59793	50534921
Joint swelling	34.00	16.97	5	10405	245281	50349433
Pneumonia aspiration	32.73	16.97	36	10374	30968	50563746
Poisoning	32.32	16.97	24	10386	12405	50582309
Urinary retention	32.23	16.97	33	10377	26157	50568557
Hypotension	32.22	16.97	114	10296	235355	50359359
Hypotonia	31.31	16.97	20	10390	8114	50586600
Newborn persistent pulmonary hypertension	31.00	16.97	7	10403	143	50594571
Arthralgia	30.86	16.97	27	10383	438675	50156039
Cor pulmonale acute	30.23	16.97	8	10402	322	50594392
Drug withdrawal syndrome neonatal	29.86	16.97	12	10398	1829	50592885
Hyperthermia	29.81	16.97	19	10391	7677	50587037
Parkinsonism	29.78	16.97	20	10390	8827	50585887
Alopecia	29.68	16.97	7	10403	245040	50349674
Mental disorder	29.43	16.97	29	10381	21962	50572752
Disturbance in attention	29.15	16.97	34	10376	31152	50563562
Diarrhoea	28.91	16.97	48	10362	588428	50006286
Post-anoxic myoclonus	28.66	16.97	5	10405	24	50594690
Polyuria	28.63	16.97	18	10392	7103	50587611
Miosis	28.04	16.97	17	10393	6293	50588421
Drug level increased	26.89	16.97	26	10384	19242	50575472
Fatigue	26.88	16.97	67	10343	707534	49887180
Inappropriate antidiuretic hormone secretion	26.84	16.97	22	10388	13121	50581593
Blood prolactin increased	26.84	16.97	13	10397	3086	50591628
Urine osmolarity increased	26.70	16.97	6	10404	120	50594594
Hallucination, auditory	26.31	16.97	20	10390	10708	50584006
Psychomotor retardation	25.63	16.97	13	10397	3405	50591309
Retroplacental haematoma	25.54	16.97	6	10404	147	50594567
Psychomotor skills impaired	25.23	16.97	11	10399	2053	50592661
Circulatory collapse	24.25	16.97	25	10385	19975	50574739
Cyanosis	24.09	16.97	22	10388	15162	50579552
Mania	23.83	16.97	19	10391	10897	50583817
Hepatocellular injury	23.77	16.97	28	10382	25919	50568795
Shock	23.58	16.97	25	10385	20625	50574089
Muscle rigidity	23.39	16.97	18	10392	9811	50584903
Spasmodic dysphonia	23.36	16.97	5	10405	79	50594635
Otorrhoea	23.22	16.97	9	10401	1247	50593467
Hypokalaemia	23.19	16.97	54	10356	87938	50506776
Obsessive-compulsive disorder	23.02	16.97	12	10398	3328	50591386
Restlessness	22.79	16.97	27	10383	25146	50569568
Product dose omission issue	22.75	16.97	5	10405	183833	50410881
Electrocardiogram QRS complex prolonged	22.73	16.97	14	10396	5330	50589384
Lactic acidosis	22.64	16.97	31	10379	33324	50561390
Asphyxia	22.53	16.97	14	10396	5413	50589301
Nephrogenic diabetes insipidus	22.48	16.97	8	10402	873	50593841
Right ventricular dilatation	21.85	16.97	8	10402	948	50593766
Rash	21.15	16.97	36	10374	437435	50157279
Hyponatraemia	21.09	16.97	55	10355	96084	50498630
Foetal arrhythmia	21.03	16.97	5	10405	129	50594585
Contraindicated product administered	20.71	16.97	3	10407	148955	50445759
Nasopharyngitis	20.59	16.97	7	10403	192920	50401794
Mydriasis	20.07	16.97	17	10393	10610	50584104
Onychophagia	19.71	16.97	4	10406	48	50594666
Peripheral swelling	19.48	16.97	9	10401	205927	50388787
Hyperhidrosis	19.45	16.97	51	10359	89375	50505339
Drug hypersensitivity	19.43	16.97	14	10396	250996	50343718
Cholestasis	19.38	16.97	25	10385	25376	50569338
Drug screen false positive	19.26	16.97	7	10403	812	50593902
Rheumatoid arthritis	18.93	16.97	9	10401	202541	50392173
Tardive dyskinesia	18.80	16.97	14	10396	7265	50587449
Treatment failure	18.61	16.97	3	10407	137634	50457080
Acquired haemophilia	18.59	16.97	7	10403	896	50593818
Apathy	18.35	16.97	14	10396	7534	50587180
Therapeutic product effect decreased	18.32	16.97	3	10407	136047	50458667
Respiratory depression	18.27	16.97	17	10393	11993	50582721
Hyporesponsive to stimuli	18.23	16.97	7	10403	945	50593769
Morbid thoughts	18.03	16.97	6	10404	536	50594178
Headache	17.63	16.97	50	10360	506485	50088229
Rhabdomyolysis	17.60	16.97	30	10380	38997	50555717
Loss of consciousness	17.33	16.97	54	10356	104299	50490415
Toxic skin eruption	17.26	16.97	16	10394	11235	50583479
Infection	17.24	16.97	7	10403	172947	50421767
Swelling	17.18	16.97	10	10400	200862	50393852
Anticholinergic syndrome	16.98	16.97	8	10402	1787	50592927

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Suicide attempt	262.56	21.69	141	7349	33969	29533068
Therapeutic product effect variable	250.51	21.69	64	7426	1813	29565224
Obsessive-compulsive disorder	247.66	21.69	77	7413	4499	29562538
Antipsychotic drug level below therapeutic	242.46	21.69	63	7427	1911	29565126
Disinhibition	229.67	21.69	64	7426	2543	29564494
Euphoric mood	210.85	21.69	69	7421	4756	29562281
Akathisia	199.44	21.69	72	7418	6670	29560367
Increased appetite	180.25	21.69	65	7425	5999	29561038
Toxicity to various agents	118.89	21.69	180	7310	173481	29393556
Serotonin syndrome	100.93	21.69	60	7430	17452	29549585
Intentional overdose	100.53	21.69	81	7409	38447	29528590
Coma	88.49	21.69	76	7414	39374	29527663
Poisoning deliberate	84.36	21.69	37	7453	5694	29561343
Dyslipidaemia	82.37	21.69	37	7453	6024	29561013
Neuroleptic malignant syndrome	76.91	21.69	49	7441	16099	29550938
Obesity	76.32	21.69	41	7449	9822	29557215
Therapeutic product effect incomplete	72.84	21.69	68	7422	39237	29527800
Leukaemia	70.71	21.69	29	7461	3781	29563256
Prescribed overdose	69.73	21.69	37	7453	8646	29558391
Electrocardiogram QT prolonged	67.88	21.69	63	7427	36074	29530963
Weight increased	66.25	21.69	89	7401	76578	29490459
Sopor	64.38	21.69	38	7452	10896	29556141
Leukopenia	61.87	21.69	73	7417	55130	29511907
Extrapyramidal disorder	54.40	21.69	34	7456	10797	29556240
Intentional self-injury	52.44	21.69	35	7455	12426	29554611
Agitation	48.04	21.69	62	7428	51242	29515795
Somnolence	44.73	21.69	83	7407	93872	29473165
Compartment syndrome	43.24	21.69	18	7472	2434	29564603
Schizoaffective disorder	41.23	21.69	14	7476	1078	29565959
Overdose	41.14	21.69	73	7417	79746	29487291
Renal hypertension	38.97	21.69	9	7481	164	29566873
Drug interaction	36.29	21.69	121	7369	197264	29369773
Loose associations	35.72	21.69	7	7483	55	29566982
Brachial plexus injury	33.85	21.69	7	7483	74	29566963
Tremor	30.12	21.69	61	7429	73477	29493560
Hypothermia	29.67	21.69	22	7468	9217	29557820
Rhabdomyolysis	29.25	21.69	54	7436	60754	29506283
Fatigue	28.72	21.69	23	7467	316798	29250239
Mania	28.65	21.69	21	7469	8642	29558395
Hypertonia neonatal	27.06	21.69	8	7482	392	29566645
Aggression	25.79	21.69	38	7452	35503	29531534
Coma scale abnormal	25.65	21.69	14	7476	3455	29563582
Pneumonia	23.50	21.69	28	7462	320144	29246893
Diarrhoea	23.48	21.69	30	7460	332668	29234369
Bradykinesia	22.99	21.69	13	7477	3434	29563603
Hyperthermia	22.81	21.69	19	7471	9411	29557626
Dyspraxia	22.74	21.69	7	7483	394	29566643
Drug withdrawal syndrome	22.15	21.69	25	7465	17959	29549078
Cough	22.04	21.69	3	7487	126724	29440313
Depressed level of consciousness	21.91	21.69	36	7454	36906	29530131

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	285.78	16.15	201	14375	87414	64396742
Serotonin syndrome	255.61	16.15	140	14436	39142	64445014
Suicide attempt	238.68	16.15	166	14410	70841	64413315
Intentional overdose	229.42	16.15	178	14398	89766	64394390
Poisoning deliberate	168.61	16.15	75	14501	13383	64470773
Neuroleptic malignant syndrome	151.32	16.15	85	14491	24911	64459245
Drug interaction	150.14	16.15	282	14294	361801	64122355
Overdose	134.99	16.15	173	14403	159393	64324763
Sopor	127.74	16.15	81	14495	29580	64454576
Toxicity to various agents	127.49	16.15	264	14312	363249	64120907
Bezoar	105.94	16.15	33	14543	2170	64481986
Electrocardiogram QT prolonged	102.22	16.15	107	14469	79341	64404815
Intentional self-injury	93.02	16.15	66	14510	28978	64455178
Akathisia	85.95	16.15	45	14531	11465	64472691
Somnolence	79.65	16.15	155	14421	203490	64280666
Depressed level of consciousness	76.26	16.15	93	14483	81343	64402813
Obsessive-compulsive disorder	73.94	16.15	31	14545	4787	64479369
Agitation	68.68	16.15	92	14484	88275	64395881
Tremor	60.57	16.15	115	14461	148115	64336041
Tachycardia	59.83	16.15	115	14461	149464	64334692
Antidepressant drug level increased	57.78	16.15	14	14562	356	64483800
Hyperthermia	56.03	16.15	38	14538	15512	64468644
Pain	54.02	16.15	29	14547	553482	63930674
Psychomotor hyperactivity	53.70	16.15	36	14540	14415	64469741
Confusional state	53.04	16.15	154	14422	260990	64223166
Antipsychotic drug level increased	53.03	16.15	25	14551	5090	64479066
Mania	52.11	16.15	37	14539	16249	64467907
Altered state of consciousness	50.41	16.15	52	14524	37850	64446306
Rhabdomyolysis	50.25	16.15	81	14495	91645	64392511
Suicidal ideation	48.24	16.15	67	14509	66475	64417681
Parkinsonism	46.79	16.15	33	14543	14340	64469816
Antipsychotic drug level below therapeutic	44.21	16.15	14	14562	971	64483185
Extrapyramidal disorder	43.97	16.15	36	14540	19516	64464640
Diarrhoea	42.61	16.15	61	14515	722643	63761513
Myoclonus	41.88	16.15	39	14537	25079	64459077
Cerebellar syndrome	41.45	16.15	21	14555	4995	64479161
Pneumonia aspiration	40.47	16.15	58	14518	59213	64424943
Fatigue	39.57	16.15	68	14508	748662	63735494
Renal hypertension	38.69	16.15	9	14567	191	64483965
Psychomotor retardation	38.08	16.15	20	14556	5123	64479033
Arthralgia	37.79	16.15	27	14549	442233	64041923
Hallucination, auditory	37.69	16.15	31	14545	16908	64467248
Sinus tachycardia	37.21	16.15	41	14535	32147	64452009
Therapeutic product effect variable	37.19	16.15	14	14562	1630	64482526
Disinhibition	36.33	16.15	15	14561	2228	64481928
Loose associations	36.18	16.15	7	14569	58	64484098
Euphoric mood	36.07	16.15	21	14555	6570	64477586
Compartment syndrome	35.80	16.15	18	14558	4214	64479942
Peripheral swelling	33.45	16.15	4	14572	209149	64275007
Hepatocellular injury	33.45	16.15	46	14530	45189	64438967
Nasopharyngitis	33.29	16.15	3	14573	196070	64288086
Prescribed overdose	32.80	16.15	31	14545	20300	64463856
Apathy	32.47	16.15	24	14552	11208	64472948
Joint swelling	32.36	16.15	5	14571	215377	64268779
Hyperchloraemia	32.20	16.15	11	14565	968	64483188
Livedo reticularis	32.08	16.15	16	14560	3681	64480475
Brachial plexus injury	32.08	16.15	7	14569	110	64484046
Urinary retention	31.91	16.15	47	14529	49154	64435002
Hypertonia	31.60	16.15	19	14557	6306	64477850
Shock	31.51	16.15	41	14535	38199	64445957
Bronchial hyperreactivity	31.45	16.15	14	14562	2498	64481658
Bradykinesia	30.96	16.15	19	14557	6541	64477615
Muscle rigidity	30.82	16.15	28	14548	17445	64466711
Schizoaffective disorder	30.49	16.15	12	14564	1575	64482581
International normalised ratio abnormal	30.26	16.15	17	14559	4971	64479185
Hyperhidrosis	29.59	16.15	78	14498	124842	64359314
Electrocardiogram QRS complex prolonged	29.57	16.15	21	14555	9223	64474933
Hyposmia	29.32	16.15	9	14567	563	64483593
Miosis	28.94	16.15	24	14552	13242	64470914
Drug abuse	28.70	16.15	80	14496	132294	64351862
Pressure of speech	28.12	16.15	10	14566	991	64483165
Post-anoxic myoclonus	28.02	16.15	5	14571	25	64484131
Coma scale abnormal	28.01	16.15	19	14557	7755	64476401
Polyuria	27.84	16.15	23	14553	12620	64471536
Ventricular dyskinesia	27.80	16.15	8	14568	400	64483756
Circulatory collapse	27.54	16.15	36	14540	33696	64450460
Obesity	26.95	16.15	28	14548	20534	64463622
Inappropriate antidiuretic hormone secretion	26.82	16.15	29	14547	22260	64461896
Asphyxia	26.67	16.15	20	14556	9546	64474610
Infusion related reaction	26.66	16.15	3	14573	164464	64319692
Retroplacental haematoma	26.42	16.15	6	14570	114	64484042
Breast disorder	26.39	16.15	11	14565	1673	64482483
Disturbance in attention	26.30	16.15	39	14537	41035	64443121
Mental disorder	26.03	16.15	31	14545	26414	64457742
Intentional product misuse	25.76	16.15	53	14523	72242	64411914
Rash	25.69	16.15	40	14536	458509	64025647
Speech disorder	25.45	16.15	42	14534	48399	64435757
Seizure	25.22	16.15	89	14487	166803	64317353
Loss of consciousness	24.94	16.15	82	14494	148283	64335873
Febrile neutropenia	24.72	16.15	6	14570	187651	64296505
Cor pulmonale acute	24.48	16.15	8	14568	614	64483542
Generalised tonic-clonic seizure	24.31	16.15	37	14539	39820	64444336
Abdominal pain	24.22	16.15	21	14555	312354	64171802
Hypothermia	24.18	16.15	26	14550	19830	64464326
Drug level increased	24.12	16.15	34	14542	34162	64449994
Blood prolactin increased	24.09	16.15	13	14563	3515	64480641
Mydriasis	24.04	16.15	23	14553	15289	64468867
Nausea	24.03	16.15	94	14482	785706	63698450
Poisoning	23.80	16.15	27	14549	21852	64462304
Psychomotor skills impaired	23.05	16.15	13	14563	3832	64480324
Pneumonia	22.64	16.15	59	14517	559517	63924639
Cough	22.60	16.15	21	14555	302127	64182029
Product dose omission issue	22.42	16.15	8	14568	194739	64289417
Hepatic cytolysis	21.86	16.15	21	14555	14028	64470128
Restlessness	21.58	16.15	35	14541	39750	64444406
Pain in extremity	21.58	16.15	22	14554	303063	64181093
Urine osmolarity increased	21.44	16.15	6	14570	271	64483885
Dyspraxia	21.31	16.15	6	14570	277	64483879
Hypotension	21.22	16.15	153	14423	380821	64103335
Anxiety	20.94	16.15	96	14480	202553	64281603
Otorrhoea	20.87	16.15	9	14567	1488	64482668
Hypokalaemia	20.15	16.15	67	14509	121836	64362320
Pleurothotonus	20.08	16.15	10	14566	2292	64481864
Product use in unapproved indication	20.00	16.15	86	14490	176532	64307624
Clonus	19.91	16.15	14	14562	6053	64478103
Morbid thoughts	19.44	16.15	7	14569	719	64483437
Death	19.43	16.15	51	14525	482654	64001502
Spasmodic dysphonia	19.13	16.15	5	14571	174	64483982
Aggression	19.01	16.15	36	14540	46196	64437960
Nephrogenic diabetes insipidus	18.88	16.15	9	14567	1878	64482278
Anticholinergic syndrome	18.69	16.15	10	14566	2659	64481497
Dyslipidaemia	18.67	16.15	16	14560	9226	64474930
Sepsis	18.44	16.15	15	14561	230326	64253830
Feelings of worthlessness	18.11	16.15	6	14570	480	64483676
Sleep disorder	18.09	16.15	41	14535	59668	64424488
Abulia	18.04	16.15	7	14569	884	64483272
Right ventricular dilatation	17.92	16.15	8	14568	1437	64482719
Hyperreflexia	17.85	16.15	14	14562	7134	64477022
Stupor	17.68	16.15	13	14563	6022	64478134
Headache	17.68	16.15	61	14515	529406	63954750
Rebound effect	17.67	16.15	12	14564	4905	64479251
Disorientation	17.65	16.15	39	14537	55789	64428367
Blood creatine phosphokinase increased	17.50	16.15	40	14536	58518	64425638
Hyponatraemia	17.39	16.15	73	14503	148266	64335890
Increased appetite	17.38	16.15	16	14560	10130	64474026
Drug screen false positive	17.18	16.15	7	14569	1005	64483151
Alopecia	17.13	16.15	8	14568	165682	64318474
Onychophagia	17.06	16.15	4	14572	88	64484068
Irritability	16.85	16.15	30	14546	36716	64447440
Hypernatraemia	16.70	16.15	17	14559	12172	64471984
Therapeutic product effect decreased	16.60	16.15	3	14573	115348	64368808

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06AA04	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Non-selective monoamine reuptake inhibitors
CHEBI has role	CHEBI:35469	antidepressants
CHEBI has role	CHEBI:48278	serotonergic drugs
CHEBI has role	CHEBI:48279	serotonin antagonists
CHEBI has role	CHEBI:149553	anticoronaviral drug
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D000929	Antidepressive Agents, Tricyclic
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D018490	Serotonin Agents
MeSH PA	D017367	Serotonin Uptake Inhibitors
FDA EPC	N0000175752	Tricyclic Antidepressant
CHEBI has role	CHEBI:50949	SSRI
CHEBI has role	CHEBI:77402	EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Obsessive-compulsive disorder	indication	191736004	DOID:10933
Depressive disorder	off-label use	35489007
Cataplexy	off-label use	46263000
Anxiety	off-label use	48694002
Panic disorder	off-label use	371631005	DOID:594
Suicidal thoughts	contraindication	6471006
Alcoholism	contraindication	7200002
Glaucoma	contraindication	23986001	DOID:1686
Hyperthyroidism	contraindication	34486009	DOID:7998
Acute nephropathy	contraindication	58574008
Epilepsy	contraindication	84757009	DOID:1826
Bipolar affective disorder, current episode manic	contraindication	191618007
Disease of liver	contraindication	235856003	DOID:409
Retention of urine	contraindication	267064002
Pheochromocytoma	contraindication	302835009
Malignant hyperthermia	contraindication	405501007
Myocardial infarction in recovery phase	contraindication	418044006
Neuroblastoma	contraindication	432328008	DOID:769
Atrioventricular Conduction Defect	contraindication

🐶 Veterinary Drug Use

Species	Use	Relation
Dogs	Separation anxiety	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Clomicalm Tablets	Virbac AH Inc.	1
Clomipramine Hydrochloride Tablets	Mizner Bioscience LLC	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.04	Basic
pKa2	6.19	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR	Kd	7.42	WOMBAT-PK	IUPHAR
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	Ki	9.70	PDSP	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.28	PDSP
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	6.24	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	7.45	PDSP
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	6.82	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	7.19	PDSP
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.95	CHEMBL
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	8.50	WOMBAT-PK
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	7.34	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	7.41	PDSP
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	8.01	DRUG MATRIX
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.70	DRUG MATRIX
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	7.66	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	7.07	DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	7.44	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	7.89	DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	7.42	DRUG MATRIX
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN		IC50	6.32	WOMBAT-PK
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	6.69	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		IC50	5.56	CHEMBL
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		Ki	5.66	WOMBAT-PK
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	7.40	DRUG MATRIX
Glutathione S-transferase P	Enzyme	P09211	GSTP1_HUMAN				WOMBAT-PK
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.71	CHEMBL
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	6.66	PDSP
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	6.95	PDSP
Trypanothione reductase	Enzyme		TYTR_TRYCR		Ki	5.19	CHEMBL
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	7.14	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	5.94	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	10.40	CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		Ki	7.25	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter		SC6A2_MOUSE		IC50	6.05	CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_MOUSE		IC50	7.15	CHEMBL
Histamine H1 receptor	GPCR		HRH1_RAT		IC50	9.70	CHEMBL
Serotonin (5-HT) receptor	GPCR		5HT2C_RAT 5HT2A_RAT 5HT1A_RAT 5HT1B_RAT 5HT1D_RAT 5HT1F_RAT 5HT2B_RAT 5HT6R_RAT 5HT7R_RAT 5HT5A_RAT 5HT5B_RAT 5HT3A_RAT 5HT4R_RAT 5HT3B_RAT		IC50	8.30	CHEMBL
Serotonin 1 (5-HT1) receptor	GPCR		5HT1A_RAT 5HT1B_RAT 5HT1D_RAT 5HT1F_RAT		Ki	5.30	CHEMBL
Adrenergic receptor alpha-2	GPCR		ADA2B_RAT ADA2C_RAT ADA2A_RAT		Ki	7.29	CHEMBL
Serotonin 2 (5-HT2) receptor	GPCR		5HT2C_RAT 5HT2A_RAT 5HT2B_RAT		Ki	8.08	CHEMBL
Trypanothione reductase	Enzyme		TYTR_TRYBB		IC50	5.47	CHEMBL
G protein-activated inward rectifier potassium channel 2	Ion channel		KCNJ6_MOUSE	BLOCKER	IC50	4.40	IUPHAR

External reference:

ID	Source
4019687	VUID
N0000147779	NUI
D00811	KEGG_DRUG
17321-77-6	SECONDARY_CAS_RN
2597	RXNORM
4019492	VANDF
4019687	VANDF
C0009010	UMLSCUI
CHEBI:47780	CHEBI
CXX	PDB_CHEM_ID
CHEMBL415	ChEMBL_ID
CHEMBL1200710	ChEMBL_ID
DB01242	DRUGBANK_ID
D002997	MESH_DESCRIPTOR_UI
2801	PUBCHEM_CID
2398	IUPHAR_LIGAND_ID
2238	INN_ID
NUV44L116D	UNII
373	MMSL
4476	MMSL
d00876	MMSL
003456	NDDF
004614	NDDF
372903001	SNOMEDCT_US
387027004	SNOMEDCT_US
96209002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-3025	CAPSULE	25 mg	ORAL	ANDA	25 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-3050	CAPSULE	50 mg	ORAL	ANDA	25 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-3075	CAPSULE	75 mg	ORAL	ANDA	25 sections
CLOMIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0406-8806	CAPSULE	25 mg	ORAL	NDA	24 sections
CLOMIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0406-8807	CAPSULE	50 mg	ORAL	NDA	24 sections
CLOMIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0406-8808	CAPSULE	75 mg	ORAL	NDA	24 sections
ANAFRANIL	HUMAN PRESCRIPTION DRUG LABEL	1	0406-9906	CAPSULE	25 mg	ORAL	NDA	24 sections
ANAFRANIL	HUMAN PRESCRIPTION DRUG LABEL	1	0406-9907	CAPSULE	50 mg	ORAL	NDA	24 sections
ANAFRANIL	HUMAN PRESCRIPTION DRUG LABEL	1	0406-9908	CAPSULE	75 mg	ORAL	NDA	24 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2027	CAPSULE	25 mg	ORAL	ANDA	25 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2037	CAPSULE	50 mg	ORAL	ANDA	25 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0630	CAPSULE	25 mg	ORAL	ANDA	24 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0631	CAPSULE	50 mg	ORAL	ANDA	24 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0632	CAPSULE	75 mg	ORAL	ANDA	24 sections
CLOMIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7038	CAPSULE	25 mg	ORAL	ANDA	26 sections
CLOMIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7039	CAPSULE	50 mg	ORAL	ANDA	26 sections
clomiPRAMINE Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10135-698	CAPSULE	25 mg	ORAL	ANDA	27 sections
clomiPRAMINE Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10135-699	CAPSULE	50 mg	ORAL	ANDA	27 sections
clomiPRAMINE Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10135-700	CAPSULE	75 mg	ORAL	ANDA	27 sections
Clomipramine Hydrochloride	Human Prescription Drug Label	1	16571-683	CAPSULE	25 mg	ORAL	ANDA	23 sections
Clomipramine Hydrochloride	Human Prescription Drug Label	1	16571-684	CAPSULE	50 mg	ORAL	ANDA	23 sections
Clomipramine Hydrochloride	Human Prescription Drug Label	1	16571-685	CAPSULE	75 mg	ORAL	ANDA	23 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16714-849	CAPSULE	25 mg	ORAL	ANDA	21 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16714-850	CAPSULE	50 mg	ORAL	ANDA	21 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16714-851	CAPSULE	75 mg	ORAL	ANDA	21 sections
Clomipramine hydrochloride	Human Prescription Drug Label	1	27241-210	CAPSULE	25 mg	ORAL	ANDA	23 sections
Clomipramine hydrochloride	Human Prescription Drug Label	1	27241-211	CAPSULE	50 mg	ORAL	ANDA	23 sections
Clomipramine hydrochloride	Human Prescription Drug Label	1	27241-212	CAPSULE	75 mg	ORAL	ANDA	23 sections
CLOMIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42571-342	CAPSULE	25 mg	ORAL	ANDA	23 sections
CLOMIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42571-343	CAPSULE	50 mg	ORAL	ANDA	23 sections